Heartburn

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule

7100%

+ 16 programs with unclassified modality

On Market (2)

Approved therapies currently available

NEXIUMApproved

esomeprazole magnesium

AstraZeneca

oral2008

74M Part D

NEXIUM 24HRApproved

esomeprazole magnesium

AstraZeneca

oral2015

Competitive Landscape

12 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

AstraZenecaCAMBRIDGE, United Kingdom

6 programs

EsomeprazolePhase 4Small Molecule1 trial

Esomeprazole MagnesiumPhase 41 trial

Esomeprazole magnesiumPhase 41 trial

esomeprazole 40 mgPhase 41 trial

EsomeprazolePhase 3Small Molecule1 trial

+1 more programs

Active Trials

NCT01370538Completed341Est. Oct 2011

NCT01370525Completed340Est. Oct 2011

NCT00625274Completed100Est. Nov 2004

+3 more trials

BayerLEVERKUSEN, Germany

2 programs

Omeprazole 20 mg + Sodium Bicarbonate 1100 mgPhase 41 trial

omeprazole/sodium bicarbonatePhase 11 trial

Active Trials

NCT01337804Completed50Est. Jan 2011

NCT01587885Completed48Est. May 2012

PfizerNEW YORK, NY

1 program

Esomeprazole 20 mgPhase 41 trial

Active Trials

NCT02708355Completed55Est. Apr 2016

SandozAustria - Kundl

3 programs

LansoprazolePhase 3Small Molecule

LanzoprazolePhase 3Small Molecule

TegaserodPhase 3

MSDIreland - Ballydine

1 program

Famotidine FCTPhase 11 trial

Active Trials

NCT00945750Completed30Est. Sep 2006

Sharp TherapeuticsPA - Pittsburgh

1 program

Famotidine FCTPhase 1

JSC Valenta PharmaceuticalsRussia - Moscow

2 programs

AntareitN/A1 trial

MagaldrateN/A1 trial

Active Trials

NCT06098742Recruiting50Est. Sep 2025

NCT06552624Completed40Est. Aug 2022

NovartisBASEL, Switzerland

2 programs

LansoprazolePHASE_3Small Molecule1 trial

LanzoprazolePHASE_3Small Molecule1 trial

Active Trials

NCT00390390Completed576Est. Jan 2007

NCT00389948Completed576Est. Jan 2007

EisaiChina - Liaoning

2 programs

rabeprazole sodiumPHASE_31 trial

Active Trials

NCT00236184Completed629Est. Jun 2008

NCT00236197Completed619Est. Jun 2008

BiocorpFrance - Issoire

1 program

Gastro-AD®N/A1 trial

Active Trials

NCT03867591Completed51Est. Dec 2019

Merck & Co.RAHWAY, NJ

1 program

Famotidine FCTPHASE_1

Johnson & JohnsonNEW BRUNSWICK, NJ

1 program

famotidinePHASE_12 trials

Active Trials

NCT04453189Completed14Est. Sep 2020

NCT00944671Completed24Est. Mar 2008

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

PfizerEsomeprazole 20 mg

BayerOmeprazole 20 mg + Sodium Bicarbonate 1100 mg

AstraZenecaesomeprazole 40 mg

AstraZenecaEsomeprazole magnesium

AstraZenecaEsomeprazole

AstraZenecaEsomeprazole Magnesium

AstraZenecaEsomeprazole

NovartisLansoprazole

NovartisLanzoprazole

Eisairabeprazole sodium

Johnson & Johnsonfamotidine

Bayeromeprazole/sodium bicarbonate

Johnson & Johnsonfamotidine

Showing 15 of 19 trials with date data

Clinical Trials (19)

Total enrollment: 4,222 patients across 19 trials

NCT02708355 PfizerEsomeprazole 20 mg

Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment

Start: Jan 2016Est. completion: Apr 201655 patients

Phase 4Completed

NCT01587885 BayerOmeprazole 20 mg + Sodium Bicarbonate 1100 mg

Comparison of Two Omeprazole-Containing Products for Relief of Frequent Heartburn (MK-0764A-036)

Start: Jan 2012Est. completion: May 201248 patients

Phase 4Completed

NCT01249651 AstraZenecaesomeprazole 40 mg

To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole

Start: Nov 2010Est. completion: Jun 2011101 patients

Phase 4Completed

NCT00206024 AstraZenecaEsomeprazole magnesium

Acid-Associated Heartburn Symptoms and Dose of Esomeprazole

Start: Nov 2004Est. completion: Jul 2005330 patients

Phase 4Completed

NCT00625274 AstraZenecaEsomeprazole

A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients

Start: Jun 2004Est. completion: Nov 2004100 patients

Phase 4Completed

NCT00637845 AstraZenecaEsomeprazole Magnesium

Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)

Start: Jun 2002Est. completion: Feb 2003248 patients

Phase 4Completed

NCT01370525 AstraZenecaEsomeprazole

Efficacy of Esomeprazole in Patients With Frequent Heartburn

Start: Aug 2011Est. completion: Oct 2011340 patients

Phase 3Completed

NCT01370538 AstraZenecaEsomeprazole

Efficacy of Esomeprazole in Patients With Frequent Heartburn

Start: Aug 2011Est. completion: Oct 2011341 patients

Phase 3Completed

NCT00390390 NovartisLansoprazole

Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn

Start: Jun 2006Est. completion: Jan 2007576 patients

Phase 3Completed

NCT00389948 NovartisLanzoprazole

Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn

Start: Jun 2006Est. completion: Jan 2007576 patients

Phase 3Completed

NCT00236197 Eisairabeprazole sodium

E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers

Start: Oct 2005Est. completion: Jun 2008619 patients

Phase 3Completed

NCT00236184 Eisairabeprazole sodium

E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers

Start: Oct 2005Est. completion: Jun 2008629 patients

Phase 3Completed

NCT04453189 Johnson & Johnsonfamotidine

A Study to Assess the Effects of Acid-Reducing Agent(s) on JNJ-64417184 in Healthy Participants

Start: Jul 2020Est. completion: Sep 202014 patients

Phase 1Completed

NCT01337804 Bayeromeprazole/sodium bicarbonate

A Study to Compare Omeprazole Administered as Zegerid® Powder and as Prilosec® Capsule in Healthy Participants (P08050)(CL2010-12)

Start: Jan 2011Est. completion: Jan 201150 patients

Phase 1Completed

NCT00944671 Johnson & Johnsonfamotidine

A Study to Assess the Bioequivalence of Famotidine/Antacid Combination Tablets Compared to Famotidine/Antacid EZ Chew Tablets (0208C-145)(COMPLETED)

Start: Feb 2008Est. completion: Mar 200824 patients

Phase 1Completed

NCT00945750 MSDFamotidine FCT

A Study to Assess the Bioequivalence of Famotidine Chewable Tablets and Film-Coated Tablets (0208-144)

Start: Aug 2006Est. completion: Sep 200630 patients

Phase 1Completed

NCT06098742 JSC Valenta PharmaceuticalsAntareit

Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers

Start: Apr 2024Est. completion: Sep 202550 patients

N/ARecruiting

NCT06552624 JSC Valenta PharmaceuticalsMagaldrate

Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg Chewable Tablets and Riopan 800 mg Chewable Tablets in Healthy Volunteers

Start: Jul 2021Est. completion: Aug 202240 patients

N/ACompleted

NCT03867591 BiocorpGastro-AD®

Fermented Soy and Heartburn Symptom Relief

Start: Mar 2019Est. completion: Dec 201951 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 4,222 patients

12 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.